At its 2026 Annual Meeting on June 18, 2026, Genprex, Inc. stockholders approved an amended and restated 2018 Equity Incentive Plan, increasing authorized common stock issuance by 1,850,000 shares. Stockholders also approved an amendment to the Certificate of Incorporation granting the Board of Directors sole discretion to implement a reverse stock split between 1:5 and 1:50 at any time before December 31, 2027. Other approved items included the election of directors Jose Antonio Moreno Toscano and Ryan M. Confer, and the ratification of WithumSmith+Brown, PC as the independent auditor. Genprex is a biotechnology company that develops therapeutic products.
